EPS for Rockwell Medical, Inc. (RMTI) Expected At $-0.13

July 13, 2018 - By Russell Jones

Rockwell Medical, Inc. (NASDAQ:RMTI) LogoInvestors sentiment increased to 0.97 in Q1 2018. Its up 0.11, from 0.86 in 2017Q4. It increased, as 7 investors sold Rockwell Medical, Inc. shares while 22 reduced holdings. 9 funds opened positions while 19 raised stakes. 10.61 million shares or 1.35% less from 10.75 million shares in 2017Q4 were reported.
Stifel Corp has invested 0% in Rockwell Medical, Inc. (NASDAQ:RMTI). Private Advisor Grp holds 0% in Rockwell Medical, Inc. (NASDAQ:RMTI) or 12,073 shares. Citigroup reported 10,047 shares. New York-based Blackrock Incorporated has invested 0% in Rockwell Medical, Inc. (NASDAQ:RMTI). Swiss Bank holds 0% or 86,100 shares. Legal And General Group Public Limited Co reported 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). Cutter And Com Brokerage has 0.04% invested in Rockwell Medical, Inc. (NASDAQ:RMTI). Synovus Financial has invested 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). New York State Common Retirement Fund holds 40,600 shares. Voya Invest Mngmt Ltd has 24,284 shares. Teacher Retirement Systems Of Texas holds 0% or 10,855 shares. Barclays Public Limited Co reported 21,347 shares. Parallax Volatility Advisers Limited Partnership holds 0% or 60 shares in its portfolio. State Street Corporation, a Massachusetts-based fund reported 913,837 shares. Great West Life Assurance Can reported 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI).

Since June 27, 2018, it had 1 buying transaction, and 0 selling transactions for $56,583 activity.

Analysts expect Rockwell Medical, Inc. (NASDAQ:RMTI) to report $-0.13 EPS on August, 8.They anticipate $0.01 EPS change or 7.14 % from last quarter’s $-0.14 EPS. After having $-0.13 EPS previously, Rockwell Medical, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.23% or $0.01 during the last trading session, reaching $4.29. About 228,314 shares traded. Rockwell Medical, Inc. (NASDAQ:RMTI) has declined 15.35% since July 13, 2017 and is downtrending. It has underperformed by 27.92% the S&P500.

Rockwell Medical, Inc. operates as an integrated biopharmaceutical firm in the United States and internationally. The company has market cap of $222.09 million. It offers services and products for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. It currently has negative earnings. The company's lead drug is Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment via dialysate.

More important recent Rockwell Medical, Inc. (NASDAQ:RMTI) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018, also Seekingalpha.com published article titled: “Rockwell Medical sues former execs over alleged self-enriching behavior”, Prnewswire.com published: “Rockwell Medical Provides Investor Update” on June 29, 2018. More interesting news about Rockwell Medical, Inc. (NASDAQ:RMTI) was released by: Nasdaq.com and their article: “Recent Analysis Shows Alamo Group, Rockwell Medical, Central Garden & Pet, Magellan Health, MaxLinear, and WD …” with publication date: June 21, 2018.

Rockwell Medical, Inc. (NASDAQ:RMTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.